Healthcare / Medical Instruments & SuppliesXETRA
$172.10
+0.85 (+0.49%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $3.4B · quality 84.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$79.0B
P/E
34.6x
↑EV/EBITDA
13.8x
↑ROE
6.0%
↑Gross Margin
60.6%
↑Debt/Equity
0.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.2%
FCF CAGR
+5.5%
FCF margin
13.2%
FCF / Net income
1.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $28.49B · net income $2.31B · FCF $3.77B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $28.49B | $28.49B | $26.51B | $25.39B | $24.49B |
| Net Income | $2.31B | $2.31B | $2.36B | $2.29B | $2.15B |
| EBITDA | $6.60B | $6.60B | $6.59B | $6.12B | $6.11B |
| EPS | 4.98 | 4.98 | 5.13 | 5.08 | 4.83 |
| Gross Margin | 60.6% | 60.6% | 63.4% | 63.2% | 63.6% |
| Operating Margin | 11.9% | 11.9% | 13.0% | 12.5% | 12.9% |
| Net Margin | 8.1% | 8.1% | 8.9% | 9.0% | 8.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.37 | 0.37 | 0.33 | 0.30 | 0.33 |
| Current Ratio | 0.99 | 0.99 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $3.77B | $3.77B | $3.35B | $3.33B | $3.21B |
| Returns | |||||
| ROE | 6.0% | 6.0% | 5.8% | 6.0% | 5.7% |
| Valuation | |||||
| P/E | 34.63 | 34.63 | 44.97 | 34.91 | 34.92 |
| EV/EBITDA | 13.76 | 13.76 | 17.76 | 14.54 | 13.98 |
| P/B | 2.06 | 2.06 | 2.63 | 2.09 | 2.01 |
| Growth & Yield | |||||
| Revenue Growth | 7.5% | 7.5% | 4.4% | 3.7% | — |
| EPS Growth | -2.9% | -2.9% | 1.0% | 5.2% | — |
| Dividend Yield | 2.3% | 2.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
45.3%
EPS terminal req.
$15.27
Spread vs growth
-48.2%
5Y implied EPS CAGR
30.0%
EPS terminal req.
$18.48
Spread vs growth
-32.9%
10Y implied EPS CAGR
19.6%
EPS terminal req.
$29.76
Spread vs growth
-22.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-25.3%
Start / end P/E
47.3x → 35.3x
EPS bridge
5.13 → 4.98
Residual
+0.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.